Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
July 10, 2020
Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19
F M A van den Heuvel, J L Vos, Y Koop, et al.
Gut
|
July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Nicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Alzheimer'S Research & Therapy
|
August 21, 2024
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic
Ilse Bader, Colin Groot, H Stevie Tan, et al.
Clinical Chemistry and Laboratory Medicine
|
January 11, 2024
Should we depend on reference intervals from manufacturer package inserts? Comparing TSH and FT4 reference intervals from four manufacturers with results from modern indirect methods and the direct method
Niek F Dirks, Wendy P J den Elzen, Jacquelien J Hillebrand, et al.
Gut
|
April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Journal of Crohn'S & Colitis
|
September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Neil Chanchlani, Simeng Lin, Desmond Chee, et al.
Gut
|
March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Nicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.
Nature Communications
|
March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
Simeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Gut
|
June 23, 2025
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Gordon W Moran, Morris Gordon, Vassiliki Sinopolou, et al.
Canadian Prosthetics & Orthotics Journal
|
April 1, 2026
A national strategy for a canadian limb loss and limb difference registry
A L Mayo, S L Hitzig, D Zidarov, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
July 10, 2020
Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19
F M A van den Heuvel, J L Vos, Y Koop, et al.
Gut
|
July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Nicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Alzheimer'S Research & Therapy
|
August 21, 2024
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic
Ilse Bader, Colin Groot, H Stevie Tan, et al.
Clinical Chemistry and Laboratory Medicine
|
January 11, 2024
Should we depend on reference intervals from manufacturer package inserts? Comparing TSH and FT4 reference intervals from four manufacturers with results from modern indirect methods and the direct method
Niek F Dirks, Wendy P J den Elzen, Jacquelien J Hillebrand, et al.
Gut
|
April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Journal of Crohn'S & Colitis
|
September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Neil Chanchlani, Simeng Lin, Desmond Chee, et al.
Gut
|
March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Nicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.
Nature Communications
|
March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
Simeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Gut
|
June 23, 2025
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Gordon W Moran, Morris Gordon, Vassiliki Sinopolou, et al.
Canadian Prosthetics & Orthotics Journal
|
April 1, 2026
A national strategy for a canadian limb loss and limb difference registry
A L Mayo, S L Hitzig, D Zidarov, et al.
Page
of 9